{
    "clinical_study": {
        "@rank": "46990", 
        "arm_group": [
            {
                "arm_group_label": "Monoprost", 
                "arm_group_type": "Experimental", 
                "description": "1 drop in each eye once daily at 9.00 pm (\u00b1 1 hour) for 3 months."
            }, 
            {
                "arm_group_label": "Lumigan 0.01%", 
                "arm_group_type": "Active Comparator", 
                "description": "1 drop in each eye once daily at 9.00 pm (\u00b1 1 hour) for 3 months."
            }, 
            {
                "arm_group_label": "Lumigan 0.03% Unit Dose", 
                "arm_group_type": "Active Comparator", 
                "description": "1 drop in each eye once daily at 9.00 pm (\u00b1 1 hour) for 3 months."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary objective:\n\n      The primary objective is to demonstrate the superiority of Monoprost\u00ae versus Lumigan\u00ae 0.01%\n      and Lumigan\u00ae 0.03% Unit Dose in term of safety with respect to the assessment of\n      conjunctival hyperaemia in the worse eye at Day 84.\n\n      The conjunctival hyperaemia will be scored using the MacMonnies photographic scale (0 to 5)."
        }, 
        "brief_title": "Safety and Efficacy Assessment of Monoprost\u00ae in Comparison With Lumigan\u00ae 0.01 % and Lumigan\u00ae 0.03% Unit Dose", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Open Angle Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged \u226518 years old.\n\n          -  Written informed consent.\n\n          -  Association of the 3 following criteria:\n\n               1. Both eyes have primary open angle glaucoma or ocular hypertension already\n                  treated and controlled by mono-therapy of Lumigan\u00ae 0.01% since at least 3 months\n                  (according to European Glaucoma Society guidelines).\n\n               2. Intra Ocular Pressure \u2264 18 mm Hg in both eyes.\n\n               3. With local intolerance signs in at least one eye defined by the association of:\n\n        3.1 Hyperaemia = Grade (2) or (3) or (4) following the photographic MacMonnies scale.\n\n        And 3.2.1 Presence of at least 2 symptoms with a level of severity \u2265 1 (= mild or moderate\n        or severe) among the following 5 symptoms: irritation/burning, itching, tearing, eye\n        dryness sensation, foreign body sensation.\n\n        And/Or 3.2.2 Presence of at least 2 signs with a level of severity \u2265 1 (= mild or moderate\n        or severe) among the following 3 signs: superficial punctate keratitis, blepharitis,\n        eyelid skin darkness.\n\n        Exclusion Criteria:\n\n          -  - Presence of at least one severe objective sign among the following:\n\n               -  Global ocular staining with Oxford (0-15) grading scheme >12.\n\n               -  Blepharitis (Grade 4: Very severe, i.e. eczematiform lesion).\n\n          -  Any ocular hypertension other than primary ocular hypertension or primary chronic\n             open angle glaucoma (such as congenital, angle closure glaucoma, secondary glaucoma).\n\n          -  Visual field not performed or not available within the 6 months before inclusion\n             visit.\n\n          -  Fundus not performed or not available within the 6 months before inclusion visit.\n\n          -  Advanced stage of glaucoma:\n\n               -  Absolute defect in the ten degrees central point of the visual field.\n\n               -  Severe visual field loss according to the investigator's best judgement.\n\n               -  Risk of visual field worsening as a consequence of participation in the trial\n                  according to the investigator's best judgement.\n\n          -  Best far corrected visual acuity \u2264 1/10.\n\n          -  History of trauma, infection, inflammation within the 3 months before inclusion\n             visit.\n\n          -  Ongoing or known history of ocular allergy and/or uveitis and/or viral infection.\n\n          -  Severe dry eye (defined by severe epithelial erosions of the cornea and/or use of dry\n             eye medication with a frequency exceeding 8 instillations / day).\n\n          -  Corneal ulceration.\n\n          -  Palpebral abnormalities not related to medical treatment study and incompatible with\n             a good evaluation.\n\n          -  Any abnormality preventing accurate assessment e.g. reliable tonometry measurement,\n             visual field examination.\n\n        Systemic/non ophthalmic/ exclusion criteria\n\n          -  Non-controlled diabetic patient.\n\n          -  Known or suspected hypersensitivity to one of the components of the study product.\n\n          -  Any medical or surgical history, disorder or disease such as acute or chronic severe\n             organic disease: hepatic, endocrine, neoplastic, haematological; immunosuppressive,\n             infectious diseases, severe psychiatric illness, relevant cardiovascular\n             abnormalities, etc\u2026 and/or any complicating factor or structural abnormality, judged\n             by the investigator to be incompatible with the study.\n\n        Specific exclusion criteria for women\n\n          -  Pregnancy, lactation.\n\n          -  Childbearing potential woman who is not using a reliable method of contraception\n             (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant,\n             vaginal ring, patch) and is not surgically sterilised."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "396", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017327", 
            "org_study_id": "LT2345-PIV-02/13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Monoprost", 
                "description": "Monoprost\u00ae: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.", 
                "intervention_name": "Monoprost", 
                "intervention_type": "Drug", 
                "other_name": "Latanoprost 0.005%"
            }, 
            {
                "arm_group_label": "Lumigan 0.01%", 
                "description": "Lumigan\u00ae 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.", 
                "intervention_name": "Lumigan 0.01%", 
                "intervention_type": "Drug", 
                "other_name": "Bimatoprost 0.1mg/ml"
            }, 
            {
                "arm_group_label": "Lumigan 0.03% Unit Dose", 
                "description": "Lumigan\u00ae 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.", 
                "intervention_name": "Lumigan 0.03% Unit Dose", 
                "intervention_type": "Drug", 
                "other_name": "Bimatoprost 0.3mg/ML"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Latanoprost", 
                "Bimatoprost"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "email": "l.bresson@laboratoires-thea.fr", 
                "last_name": "Lydia Bresson", 
                "phone": "04 73 98 95 07"
            }, 
            "facility": {
                "address": {
                    "city": "Clermont ferrand", 
                    "country": "France", 
                    "zip": "63000"
                }, 
                "name": "Laboratoires Th\u00e9a"
            }, 
            "investigator": {
                "last_name": "Christophe Baudouin, Professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "Safety and Efficacy Assessment of Monoprost\u00ae in Comparison With Lumigan\u00ae 0.01% and Lumigan\u00ae 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan\u00ae 0.01% With Ocular Surface Intolerance", 
        "overall_official": {
            "affiliation": "Hopital des XV-XX", 
            "last_name": "Christophe Baudouin, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agance Nationale de S\u00e9curit\u00e9 des M\u00e9dicaments et des Produits de Sant\u00e9", 
                "Espagne: Agencia Espanola de Medicamentos y Productos Sanitarios", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the change from baseline of conjunctival hyperaemia assessed on MacMonnies' 6 point ordinal scale, in the worse eye at the D84 visit.  The primary statistical hypothesis tested is that Monoprost\u00ae is superior to Lumigan\u00ae 0.03% Unit Dose with regard to this primary endpoint, i.e. that in the worse eye the decrease from baseline in the MacMonnies 6 point ordinal scale is greater in the Monoprost\u00ae treated group than in the Lumigan\u00ae 0.03% Unit Dose group at the Day 84 visit.", 
            "measure": "safety with respect to the assessment of conjunctival hyperaemia in the Worse eye", 
            "safety_issue": "Yes", 
            "time_frame": "Day 84"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017327"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The major secondary endpoint is response to treatment defined as a mean Intra Ocular Pressure \u2264 18 mm Hg and a decrease in MacMonnies scale from baseline of at least 1 point in the worse eye at the D84 visit.", 
            "measure": "Response to treatment", 
            "safety_issue": "No", 
            "time_frame": "Day 84"
        }, 
        "source": "Laboratoires Thea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Laboratoires Thea", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}